What is Global Innovative Platforms Inc?
engages in the business of testing breath to detect and assist in the treatment of disease.
GIPL · Verdict
Moderate reward · elevated risk
GIPL's standout is balance sheet; cash flow and volatility weigh on the picture.
Based on 75% data coverage
GIPL · Verdict
Current ratio 17.17
Weak vs peers
Weak vs peers
-441% return on equity
Model-based scoring. For information only — not financial advice.
engages in the business of testing breath to detect and assist in the treatment of disease. The company develops Heartworm breath test, which includes breath collection device, to collect shallow breath samples. The company is listed on the PINK in USA, operating in the Financial Services sector, with a market capitalisation of 317.02K.
The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.